EFFECT OF GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) ON CHEMOTHERAPY-INDUCED ORAL MUCOSITIS

被引：31

作者：

KATANO, M

NAKAMURA, M

MATSUO, T

IYAMA, A

HISATSUGU, T

机构：

[1] Department of Surgery, Saga Medical School, Saga, 849

来源：

SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY | 1995年 / 25卷 / 03期

关键词：

ORAL MUCOSITIS; GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF); ADRIAMYCIN; CHEMOTHERAPY;

D O I：

10.1007/BF00311527

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

In this study, the ability of granulocyte colony-stimulating factor (G-CSF) to treat or prevent chemotherapy-induced oral mucositis in patients with advanced breast cancer was evaluated. A total of 14 patients who received intraarterial (i.a.) adriamycin (ADM) preoperatively were divided into two groups according to whether or not G-CSF was given. Thus, group A (n = 7) was given G-CSF and group B (n = 7) was not. G-CSF therapy reduced both the incidence and duration of ADM-induced oral mucositis, and a positive correlation was also seen between the incidence of mucositis and ADM-induced leukopenia (<2,000/mm(3)). Group A was further divided into two subgroups according to whether G-CSF was given after or before the leukopenia had dropped below 2,000/mm(3): group A-1 (n = 3) and group A-2 (n = 4), respectively. ADM-induced mucositis was observed in two of the three patients in group A-1, but in none of the four patients in group A-2. These results strongly support the idea that G-CSF can effectively treat and prevent ADM-induced oral mucositis.

引用

页码：202 / 206

页数：5

共 31 条

[1]

Samueles B.L., Vogelzang N.J., Ruane M., Simon M.A., Continuous venous infusion of doxorubicin in advanced sarcomas, Cancer Treat Rep, 71, pp. 971-972, (1987)

[2]

Poon M.A., O'Connell M.J., Moertel C.G., Wieand H.S., Cullinan S.A., Everson L.K., Krook J.E., Mailliard J.A., Laurie J.A., Tschetter L.K., Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma, J Clin Oncol, 7, pp. 1407-1418, (1989)

[3]

Hederson J.C., Allegra J.C., Woodcock T., Wolff S., Bryan S., Cartwright K., Dukart G., Henry D., Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer, J Clin Oncol, 7, pp. 560-571, (1989)

[4]

Gabizon A., Peretz T., Sulkes A., Aelem S., Ben-Yosef R., Ben-Baruch N., Catane R., Biran S., Berenholz Y., Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study, Eur J Cancer Clin Oncol, 25, pp. 1795-1803, (1989)

[5]

Hortobagyi G.N., Frye D., Buzdar A.U., Ewer, Fraschini G., Hug V., Ames F., Montague E., Carrasco C.H., Mackay B., Benjamin R.S., Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma, Cancer, 63, pp. 37-45, (1989)

[6]

Mohood D.J., Dose A.M., Loprinzi C.L., Veeder M.H., Athmann L.M., Therneou T.M., Sorensen J.M., Gainey D.K., Malliard J.A., Gusa N.L., Finck G.K., Johnson C., Goldberg R.M., Inhibition of fluorouracil-induced stomatitis by oral cryotherapy, J Clin Oncol, 9, pp. 449-452, (1991)

[7]

Roth B.J., Sledge G.W., Willia S.D., Meyer S.C., Ansari R., Fisher W.B., Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer, Cancer, 68, pp. 248-252, (1991)

[8]

Carmo-Perrira J., Costa F.O., Miles D.W., Henrigues E., Richards M.A., Rubens R.D., High-dose epirubicin as primary chemotherapy in advanced breast carcinoma

[9]

a phase II study, Cancer Chemotherapy and Pharmacology, 27, pp. 394-396, (1991)

[10]

Reimann H.A., deBerardinis C.T., Periodic (cyclic) neutropenia, an entity, Blood, 4, pp. 1109-1116, (1949)

← 1 2 3 4 →